Drug Trial Radar · NCT00897104
MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
933
Actual
Start
Aug 1995
Primary completion
May 1996
Study completion Sep 1996
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.
Conditions
- Migraine Headache
Interventions
rizatriptan benzoate (MK0462)Drug
single dose 5 mg rizatriptan p.o.
Comparator: sumatriptanDrug
single dose 50 mg sumatriptan p.o.
Comparator: PlaceboDrug
Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Relief at 2 Hours After TreatmentTime frame: 2 hours after treatment
- Time to Relief Within 2 Hours After TreatmentTime frame: within 2 hours after treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.